SYNAIRGEN LIMITED

• ⚠

  Material uncertainty over going concern

  The ability of the Group and the Company to raise further capital to extend the cash runway up to and beyond the going concern period is outside the control of the directors and therefore represents a material uncertainty regarding the Group and the Company's ability to continue as a going concern.

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. SYNAIRGEN LIMITED 2025-05-19 → present
2. SYNAIRGEN PLC 2004-10-12 → 2025-05-19
3. SYNAIRGEN RESEARCH PLC 2004-09-16 → 2004-10-12

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The ability of the Group and the Company to raise further capital to extend the cash runway up to and beyond the going concern period is outside the control of the directors and therefore represents a material uncertainty regarding the Group and the Company's ability to continue as a going concern.”

Group structure

1. SYNAIRGEN LIMITED · parent
   1. Synairgen Research Limited 100% · United Kingdom · Drug discovery and development
   2. Synairgen Research (Ireland) Limited 100% · Ireland · Pharmaceutical commercialisation
   3. Synairgen Inc 100% · USA · Pharmaceutical commercialisation

Significant events

• “Finalised a comprehensive and focused strategic review of the future development of our lead asset, SNG001, a broad-spectrum lung-targeted antiviral.”
• “Company launched a fundraise to progress the INVENT trial, which concluded successfully post period end in January 2025, raising £18 million of gross proceeds.”
• “The Company's admission of Ordinary Shares to trading on AIM was cancelled post period end on 9 April 2025.”
• “On 17 January 2025, TFG Asset Management UK LLP invested £18.0m to acquire 900m shares, this took their holding from 58m ordinary shares (28.8%) to 958m ordinary shares (86.9%), resulting in them becoming the ultimate controlling party.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -56.7%

  £10,516,000 → £4,554,000

• Net assets

  -50.4%

  £12,657,000 → £6,278,000

• Employees

  +3%

  33 → 34

• Operating profit

  +19.1%

  -£10,292,000 → -£8,324,000

• Profit before tax

  +17.9%

  -£9,657,000 → -£7,929,000

• Wages

  -3.9%

  £2,974,000 → £2,857,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers